The invention relates to a fusion protein, designated as TAT-RH, comprising a first segment consisting of the minimal sequence of the HIV-TAT transduction domain and a second segment consisting of the RH region of the GRK5 kinase. Advantageously, the TAT- RH fusion protein is capable of penetrating into an eukaryotic cell without the help provided by vectors, and is capable of increasing cell apoptosis. These properties make the TAT-RH fusion protein according to the invention particularly suitable as an anti-tumor medicament. The invention further describes the nucleic acid sequence encoding for the TAT-RH fusion protein, a host cell transformed with the nucleic acid encoding for TAT- RH, as well as a method for the manufacture of TAT-RH by recombinant means.
A FUSION PROTEIN HAVING ANTITUMOR ACTIVITY / Iaccarino, Guido; Trimarco, Bruno; Sorriento, D.. - (2009).
A FUSION PROTEIN HAVING ANTITUMOR ACTIVITY
IACCARINO, GUIDO;TRIMARCO, BRUNO;SORRIENTO D.
2009
Abstract
The invention relates to a fusion protein, designated as TAT-RH, comprising a first segment consisting of the minimal sequence of the HIV-TAT transduction domain and a second segment consisting of the RH region of the GRK5 kinase. Advantageously, the TAT- RH fusion protein is capable of penetrating into an eukaryotic cell without the help provided by vectors, and is capable of increasing cell apoptosis. These properties make the TAT-RH fusion protein according to the invention particularly suitable as an anti-tumor medicament. The invention further describes the nucleic acid sequence encoding for the TAT-RH fusion protein, a host cell transformed with the nucleic acid encoding for TAT- RH, as well as a method for the manufacture of TAT-RH by recombinant means.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
